Status:
COMPLETED
Intermittent Preventive Treatment With Antimalarials in Kenyan Infants
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborating Sponsors:
Kenya Medical Research Institute
Bill and Melinda Gates Foundation
Conditions:
Malaria
Anemia
Eligibility:
All Genders
5-16 years
Phase:
NA
Brief Summary
The purpose of the study is to see whether antimalarial drugs administered at the time of routine infant vaccinations prevents malaria and anemia in the first year of life.
Detailed Description
Approximately three quarters of preschool children in eastern Africa suffer from anemia, defined as a hemoglobin (Hb) concentration below 11 g/dL. For children \< 5 years of age, the overall incidence...
Eligibility Criteria
Inclusion
- Presenting for Pentavalent 1 immunization
- Age 5 weeks to 16 weeks
- Parent or guardian currently resident in study catchment area
- Parent or guardian has given permission for their child to participate
Exclusion
- Known allergy to any of the study drugs
- Current Cotrimoxazole prophylaxis
- Concomitant disease requiring hospitalization or transfusion
- Plans to be away from the study area for more than 6 months during the next year
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2008
Estimated Enrollment :
1516 Patients enrolled
Trial Details
Trial ID
NCT00111163
Start Date
March 1 2004
End Date
March 1 2008
Last Update
September 27 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lwak, Abidha, Ongielo and Saradidi clinics
Asembo (Rarieda Division), Nyanza Province, Kenya